Aging
Navigate
Submit an Article
Research Paper|Volume 10, Issue 10|pp 2900—2910

Can mesenchymal stem cell lysate reverse aging?

Ming-Fen Hsu1, Szu-Hsien Yu1, Sheng-Ju Chuang1,2, Tom Kwang-Chun Kuo3, Pawan K. Singal4, Chih-Yang Huang5,6, Chung-Lan Kao7, Chia-Hua Kuo1
  • 1Laboratory of Exercise Biochemistry, University of Taipei, Taipei, Taiwan
  • 2Université Catholique de Louvain and de Duve Institute, Brussels, Belgium
  • 3Stem Cell Research Center, National Yang-Ming University, Taipei, Taiwan
  • 4Institute of Cardiovascular Sciences, St Boniface General Hospital Research Centre and Department of Physiology and Pathophysiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
  • 5Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan
  • 6Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan
  • 7Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital and National Yang Ming University, Taipei, Taiwan

* * Equal contribution

Received: August 21, 2018Accepted: October 12, 2018Published: October 24, 2018
https://doi.org/10.18632/aging.101595

Copyright: © 2018 Hsu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Recent findings regarding uses of adipose-derived mesenchymal stem cell (MSC)-lysate on weight loss and improved glucose tolerance in mice on a high-fat diet suggest an encouraging possibility of using MSC lysate for an anti-aging intervention in humans. However, weight loss and lipopenia during late life can be as life-threatening as hyperglycemia during early adulthood. For this 3-year lifelong experiment, a total of 92 rats were randomized into the vehicle-injected group (F=22; M=24) and the MSC lysate injected group (F=22, M=24). We examined longevity, spontaneous locomotor activity, and body composition in rats maintained on a normal diet and received an intermittent treatment of human adipose-derived MSC lysate (3 times a week, 11 times a month given every second month), starting at 12 months of age until natural death. In substantiating previous knowledge regarding the effects of long-term MSC lysate treatments on fat loss and insulin resistance, the present findings also highlighted a shortened average lifespan, a longer inactive time, and a greater bone loss with a relative increase of lean mass in MSC lysate rats with respect to controls. Conclusion: Our data suggest that MSC lysate treatments stimulate disparity in tissue development and produce a cachexia-like effect to decrease longevity.